1. Home
  2. Analysis
  3. Ceftazidime
  4. Iressa

Ceftazidime and Iressa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftazidime (ceftazidime) and Iressa (gefitinib). Common drug interactions include peritonitis among females and intestinal obstruction among males.

The phase IV clinical study analyzes what interactions people have when they take Ceftazidime and Iressa. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

What is Iressa?

Iressa has active ingredients of gefitinib. eHealthMe is studying from 10,102 Iressa users. Check the latest studies of Iressa.

On Jul, 10, 2026

11 people who take Ceftazidime and Iressa together, and have interactions are studied.

Ceftazidime and Iressa drug interactions.

What are the common drug interactions of Ceftazidime and Iressa, by gender? *:

female:

  1. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)
  2. Abdominal pain
  3. Adverse reaction
  4. Muscle tightness
  5. Somnolence (a state of near-sleep, a strong desire for sleep)

male:

  1. Intestinal obstruction
  2. Abdominal distension
  3. Constipation
  4. Gastrointestinal pain
  5. Lung disorder (lung disease)

What are the common drug interactions of Ceftazidime and Iressa, by age (0-1 to 60+)? *:

0-1:

  1. Intestinal obstruction

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Somnolence (a state of near-sleep, a strong desire for sleep)

50-59:

n/a

60+:

  1. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)
  2. Intestinal obstruction
  3. Abdominal distension
  4. Abdominal pain
  5. Adverse reaction
  6. Constipation
  7. Gastrointestinal pain
  8. Lung disorder (lung disease)
  9. Muscle tightness

What are the existing conditions these people have? *

  1. Metastases To Central Nervous System (cancer spreads to central nervous system): 5 people, 45.45%
  2. Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 27.27%
  3. Infection: 3 people, 27.27%
  4. Cardiac Disorder: 2 people, 18.18%
  5. Pneumonia: 1 person, 9.09%
  6. Metastasis (spreadable cancer to other organ from origin): 1 person, 9.09%
  7. Lung Infection: 1 person, 9.09%
  8. Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 9.09%
  9. Lip And/or Oral Cavity Cancer (cancer of lip or mouth): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and Iressa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ceftazidime and Iressa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Iressa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ceftazidime and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Iressa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime and gefitinib (the active ingredients of Ceftazidime and Iressa, respectively), and Ceftazidime and Iressa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.